---
title: "Blueprint Medicines Corp reports results for the quarter ended December 31 - Earnings Summary"
date: "2025-02-13 23:14:21"
summary: "Blueprint Medicines Corp reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.82. The mean expectation of twenty analysts for the quarter was for a loss of 70 cents per..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Blueprint Medicines Corp reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.82. The mean expectation of twenty analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from $-1.24 to -51 cents per share.
* Revenue rose 103.4% to $146.37 million from a year ago; analysts expected $145.84 million.
* Blueprint Medicines Corp's reported EPS for the quarter was a loss of 79 cents​.
* The company reported a quarterly loss of $49.96 million.
* Blueprint Medicines Corp shares had risen by 18.7% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.​
* In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Blueprint Medicines Corp is $128.50

This summary was machine generated from LSEG data February 13 at 03:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact [RefinitivNewsSupport@thomsonreuters.com](http://mailto:RefinitivNewsSupport@thomsonreuters.com))

| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| --- | --- | --- | --- |
| Dec. 31 2024 | -0.70 | -0.79 | Missed |
| Sep. 30 2024 | -0.97 | -0.89 | Beat |
| Jun. 30 2024 | -1.29 | -0.80 | Beat |
| Mar. 31 2024 | -1.66 | -1.32 | Beat |

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3P4247:0-blueprint-medicines-corp-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
